![Marcia Belvin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 593 737 $ al 31/05/2026
Marcia P.
Belvin is currently Chief Scientific Officer & Senior Vice President at CytomX Therapeutics, Inc., a position held since 2022.
Education includes an undergraduate degree from Harvard University and a doctorate from the University of California, Berkeley.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/04/2026 | 164.927 ( 0,08 % ) | 593 737 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/12/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
Elige MarketScreener 
